{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:37:31Z","timestamp":1792618651584,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s40119-019-00150-w","type":"journal-article","created":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T15:04:07Z","timestamp":1570028647000},"page":"179-191","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":100,"title":["A Review of the Role of Bradykinin and Nitric Oxide in the Cardioprotective Action of Angiotensin-Converting Enzyme Inhibitors: Focus on Perindopril"],"prefix":"10.1007","volume":"8","author":[{"given":"Arnaud","family":"Ancion","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Tridetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai-Linh","family":"Nguyen Trung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Oury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizio","family":"Lancellotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,1]]},"reference":[{"issue":"1","key":"150_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2017.04.052","volume":"70","author":"GA Roth","year":"2017","unstructured":"Roth GA, Johnson C, Abaiobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1\u201325.","journal-title":"J Am Coll Cardiol"},{"key":"150_CR2","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1161\/CIRCULATIONAHA.106.655688","volume":"114","author":"VJ Dzau","year":"2006","unstructured":"Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes part I: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. 2006;114:2850\u201370.","journal-title":"Circulation"},{"issue":"6","key":"150_CR3","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1177\/1358863X10382946","volume":"15","author":"MF O\u2019Rourke","year":"2010","unstructured":"O\u2019Rourke MF, Safar ME, Dzau V. The cardiovascular continuum extended: aging effects on the aorta and microvasculature. Vasc Med. 2010;15(6):461\u20138.","journal-title":"Vasc Med"},{"key":"150_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/bja\/aeh163","volume":"93","author":"HF Galley","year":"2004","unstructured":"Galley HF, Webster NR. Physiology of the endothelium. Br J Anaesth. 2004;93:105\u201313.","journal-title":"Br J Anaesth"},{"key":"150_CR5","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1161\/01.CIR.0000153339.27064.14","volume":"111","author":"A Lerman","year":"2005","unstructured":"Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation. 2005;111:363\u20138.","journal-title":"Circulation"},{"issue":"3","key":"150_CR6","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S0008-6363(00)00103-6","volume":"47","author":"D Tomasian","year":"2000","unstructured":"Tomasian D, Keaney JF, Vita JA. Antioxidants and the bioactivity of endothelium-derived nitric oxide. Cardiovasc Res. 2000;47(3):426\u201335.","journal-title":"Cardiovasc Res"},{"key":"150_CR7","doi-asserted-by":"publisher","first-page":"II3","DOI":"10.1002\/j.1932-8737.1997.tb00006.x","volume":"20","author":"TF L\u00fcscher","year":"1997","unstructured":"L\u00fcscher TF, Barton M. Biology of the endothelium. Clin Cardiol. 1997;20:II3\u201310.","journal-title":"Clin Cardiol"},{"key":"150_CR8","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.2174\/1381612033453866","volume":"9","author":"S Taddei","year":"2003","unstructured":"Taddei S, Ghiadoni L, Virdis A, Versari D, Salvetti A. Mechanisms of endothelial dysfunction: clinical significance and preventive non-pharmacological therapeutic strategies. Curr Pharm Des. 2003;9:2385\u2013402.","journal-title":"Curr Pharm Des"},{"issue":"4","key":"150_CR9","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1161\/01.HYP.37.4.1047","volume":"37","author":"VJ Dzau","year":"2001","unstructured":"Dzau VJ. Theodore Cooper Lecture. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension. 2001;37(4):1047\u201352.","journal-title":"Hypertension"},{"key":"150_CR10","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S1054-3589(08)60498-6","volume":"28","author":"KK Griendling","year":"1994","unstructured":"Griendling KK, Lass\u00e8gue B, Murphy TJ, Alexander RW. Angiotensin II receptor pharmacology. Adv Pharmacol. 1994;28:269\u2013306.","journal-title":"Adv Pharmacol"},{"key":"150_CR11","doi-asserted-by":"publisher","first-page":"27540","DOI":"10.1074\/jbc.M114.604231","volume":"289","author":"S Kossmann","year":"2014","unstructured":"Kossmann S, Hu H, Steven S, et al. Inflammatory monocytes determine endothelial nitric-oxide synthase uncoupling and nitro-oxidative stress induced by angiotensin II. J Biol Chem. 2014;289:27540\u201350.","journal-title":"J Biol Chem"},{"key":"150_CR12","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1161\/01.RES.84.9.1043","volume":"84","author":"DT Li","year":"1999","unstructured":"Li DT, Zhang YC, Philips MI, Sawamura T, Mehta JL. Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation. Circ Res. 1999;84:1043\u20139.","journal-title":"Circ Res"},{"key":"150_CR13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1161\/01.HYP.0000153321.13792.b9","volume":"45","author":"T Watanabe","year":"2005","unstructured":"Watanabe T, Barker TA, Berk BC. Angiotensin II and the endothelium: diverse signals and effects. Hypertension. 2005;45:163\u20139.","journal-title":"Hypertension"},{"key":"150_CR14","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1097\/01.LAB.0000017372.76297.EB","volume":"82","author":"R Tamarat","year":"2002","unstructured":"Tamarat R, Silvestre JS, Durie M, Levy BI. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways. Lab Investig. 2002;82:747\u201356.","journal-title":"Lab Investig"},{"key":"150_CR15","doi-asserted-by":"publisher","first-page":"C779","DOI":"10.1152\/ajpcell.00398.2003","volume":"286","author":"IA Arenas","year":"2004","unstructured":"Arenas IA, Xu Y, Lopez-Jaramillo P, Davidge ST. Angiotensin II-induced MMP-2 release from endothelial cells is mediated by TNF-alpha. Am J Physiol Cell Physiol. 2004;286:C779\u201384.","journal-title":"Am J Physiol Cell Physiol"},{"key":"150_CR16","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1172\/JCI118807","volume":"98","author":"BI Levy","year":"1996","unstructured":"Levy BI, Benessiano J, Henrion D, et al. Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. J Clin Investig. 1996;98:418\u201325.","journal-title":"J Clin Investig"},{"key":"150_CR17","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1161\/01.CIR.87.6.1969","volume":"87","author":"PM Ridker","year":"1993","unstructured":"Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin\u2013angiotensin system and fibrinolytic function. Circulation. 1993;87:1969\u201373.","journal-title":"Circulation"},{"issue":"1","key":"150_CR18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/MNH.0b013e32834d54b1","volume":"21","author":"Y Kayashima","year":"2012","unstructured":"Kayashima Y, Smithies O, Kakoki M. The kallikrein\u2013kinin system and oxidative stress. Curr Opin Nephrol Hypertens. 2012;21(1):92\u20136.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"2","key":"150_CR19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.npep.2009.12.004","volume":"44","author":"F Kuhr","year":"2010","unstructured":"Kuhr F, Lowry J, Zhang Y, et al. Differential regulation of inducible and endothelial nitric oxide synthase by kinin B1 and B2 receptors. Neuropeptides. 2010;44(2):145\u201354.","journal-title":"Neuropeptides"},{"key":"150_CR20","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.2174\/138161206778194051","volume":"12","author":"JB Su","year":"2006","unstructured":"Su JB. Kinins and cardiovascular diseases. Curr Pharm Des. 2006;12:3423\u201335.","journal-title":"Curr Pharm Des"},{"key":"150_CR21","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1161\/01.CIR.101.15.1848","volume":"101","author":"JB Su","year":"2000","unstructured":"Su JB, Ho\u00fcel R, H\u00e9loire F, et al. Stimulation of bradykinin B(1) receptors induces vasodilation in conductance and resistance coronary vessels in conscious dogs: comparison with B(2) receptor stimulation. Circulation. 2000;101:1848\u201353.","journal-title":"Circulation"},{"key":"150_CR22","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1177\/1470320312474854","volume":"15","author":"JB Su","year":"2014","unstructured":"Su JB. Different cross-talk sites between the renin\u2013angiotensin and the kallikrein\u2013kinin systems. J Renin Angiotensin Aldosterone Syst. 2014;15:319\u201328.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"150_CR23","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s40256-016-0173-4","volume":"16","author":"S Taddei","year":"2016","unstructured":"Taddei S, Bortolotto L. Unraveling the pivotal role of bradykinin in ACE inhibitor activity. Am J Cardiovasc Drugs. 2016;16:309\u201321.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"1","key":"150_CR24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3109\/10623329709044160","volume":"5","author":"B Baudin","year":"1997","unstructured":"Baudin B, Berard M, Carrier JL, et al. Vascular origin deter-mines angiotensin I-converting enzyme expression in endothelial cells. Endothelium. 1997;5(1):73\u201384.","journal-title":"Endothelium"},{"issue":"3","key":"150_CR25","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.jacc.2006.04.074","volume":"48","author":"S Taddei","year":"2006","unstructured":"Taddei S, Versari D, Cipriano A, et al. Identification of a cytochrome P450 2C9-derived endothelium-derived hyperpo-larizing factor in essential hypertensive patients. J Am Coll Cardiol. 2006;48(3):508\u201315.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"150_CR26","doi-asserted-by":"publisher","first-page":"e12757","DOI":"10.1371\/journal.pone.0012757","volume":"5","author":"JP Bentley","year":"2010","unstructured":"Bentley JP, Asselbergs FW, Coffey CS, et al. Cardiovascular risk associated with interactions among polymorphisms in genes from the renin\u2013angiotensin, bradykinin, and fibrinolytic systems. PLoS One. 2010;5(9):e12757.","journal-title":"PLoS One"},{"issue":"8","key":"150_CR27","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1161\/01.ATV.20.8.2019","volume":"20","author":"B Wiman","year":"2000","unstructured":"Wiman B, Andersson T, Hallqvist J, et al. Plasma levels of tissue plasminogen activator\/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscler Thromb Vasc Biol. 2000;20(8):2019\u201323.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"150_CR28","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1159\/000362666","volume":"51","author":"AM Rahman","year":"2014","unstructured":"Rahman AM, Murrow JR, Ozkor MA, et al. Endothelium-derived hyperpolarizing factor mediates bradykinin-stimulated tissue plasminogen activator release in humans. J Vasc Res. 2014;51(3):200\u20138.","journal-title":"J Vasc Res"},{"issue":"22","key":"150_CR29","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1161\/01.CIR.97.22.2222","volume":"97","author":"S Taddei","year":"1998","unstructured":"Taddei S, Virdis A, Ghiadoni L, et al. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation. 1998;97(22):2222\u20139.","journal-title":"Circulation"},{"issue":"Suppl 2","key":"150_CR30","doi-asserted-by":"publisher","first-page":"S314","DOI":"10.2337\/dc09-S330","volume":"32","author":"D Versari","year":"2009","unstructured":"Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S. Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care. 2009;32(Suppl 2):S314\u201321.","journal-title":"Diabetes Care"},{"key":"150_CR31","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s11906-011-0207-x","volume":"13","author":"A Virdis","year":"2011","unstructured":"Virdis A, Ghiadoni L, Taddei S. Effects of antihypertensive treatment on endothelial function. Curr Hypertens Rep. 2011;13:276\u201381.","journal-title":"Curr Hypertens Rep"},{"issue":"5","key":"150_CR32","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1097\/HJH.0b013e3280bad9b4","volume":"25","author":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration","year":"2007","unstructured":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration. Blood pressure-dependent and independent effects of agents that inhibit the renin\u2013angiotensin system. J Hypertens. 2007;25(5):951\u20138.","journal-title":"J Hypertens"},{"issue":"16","key":"150_CR33","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1093\/eurheartj\/ehs075","volume":"33","author":"LC van Vark","year":"2012","unstructured":"van Vark LC, Bertrand M, Akkerhuis KM, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin\u2013angiotensin\u2013aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012;33(16):2088\u201397.","journal-title":"Eur Heart J"},{"issue":"22","key":"150_CR34","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1161\/CIRCULATIONAHA.117.026112","volume":"135","author":"MH Strauss","year":"2017","unstructured":"Strauss MH, Hall AS. Angiotensin receptor blockers do not reduce risk of myocardial infarction, cardiovascular death, or total mortality: further evidence for the ARB-MI paradox. Circulation. 2017;135(22):2088\u201390.","journal-title":"Circulation"},{"key":"150_CR35","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/00004872-200403000-00016","volume":"22","author":"A Virdis","year":"2004","unstructured":"Virdis A, Neves MF, Amiri F, Touyz RM, Schiffrin EL. Role of NAD(P)H oxidase on vascular alterations in angiotensin II-infused mice. J Hypertens. 2004;22:535\u201342.","journal-title":"J Hypertens"},{"key":"150_CR36","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.cardiores.2006.10.021","volume":"73","author":"C Ceconi","year":"2007","unstructured":"Ceconi C, Fox KM, Remme WJ, EUROPA Investigators, PERTINENT Investigators and the Statistical Committee, et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res. 2007;73:237\u201346.","journal-title":"Cardiovasc Res"},{"key":"150_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejphar.2007.07.061","volume":"577","author":"C Ceconi","year":"2007","unstructured":"Ceconi C, Francolini G, Olivares A, Comini L, Bachetti T, Ferrari R. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol. 2007;577:1\u20136.","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"150_CR38","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10557-007-6068-5","volume":"21","author":"C Ceconi","year":"2007","unstructured":"Ceconi C, Francolini G, Bastianon D, et al. Differences in the effect of angiotensin-converting enzyme inhibitors on the rate of endothelial cell apoptosis in vitro and in vivo studies. Cardiovasc Drugs Ther. 2007;21(6):423\u20139.","journal-title":"Cardiovasc Drugs Ther"},{"key":"150_CR39","first-page":"531","volume":"51","author":"PK Goon","year":"2005","unstructured":"Goon PK, Boos CJ, Lip GY. Circulating endothelial cells: markers of vascular dysfunction. Clin Lab. 2005;51:531\u20138.","journal-title":"Clin Lab"},{"key":"150_CR40","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s10557-010-6244-x","volume":"24","author":"R Ferrari","year":"2010","unstructured":"Ferrari R, Guardigli G, Ceconi C. Secondary prevention of CAD with ACE inhibitors: a struggle between life and death of the endothelium. Cardiovasc Drug Ther. 2010;24:331\u20139.","journal-title":"Cardiovasc Drug Ther"},{"key":"150_CR41","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1161\/HYPERTENSIONAHA.107.109066","volume":"51","author":"D You","year":"2008","unstructured":"You D, Cochain C, Loinard C, et al. Hypertension impairs postnatal vasculogenesis: role of antihypertensive agents. Hypertension. 2008;51:1537\u201344.","journal-title":"Hypertension"},{"key":"150_CR42","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.jacc.2009.10.061","volume":"55","author":"C Vlachopoulos","year":"2010","unstructured":"Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55:1318\u201327.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"150_CR43","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/01.HYP.0000224283.76347.8c","volume":"48","author":"AI Tropeano","year":"2006","unstructured":"Tropeano AI, Boutouyrie P, Pannier B, et al. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension. 2006;48(1):80\u20136.","journal-title":"Hypertension"},{"key":"150_CR44","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1161\/CIRCULATIONAHA.105.595496","volume":"113","author":"B Williams","year":"2006","unstructured":"Williams B, Lacy PS, Thom SM, CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:1213\u201325.","journal-title":"Circulation"},{"key":"150_CR45","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/MCA.0b013e32832fa9b8","volume":"20","author":"N Bruining","year":"2009","unstructured":"Bruining N, deWinter S, Roelandt J, et al. Coronary calcium significantly affects quantitative analysis of coronary ultrasound: importance for atherosclerosis progression\/regression studies. Coron Artery Dis. 2009;20:409\u201314.","journal-title":"Coron Artery Dis"},{"issue":"2","key":"150_CR46","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.amjcard.2007.02.073","volume":"100","author":"GA Rodriguez-Granillo","year":"2007","unstructured":"Rodriguez-Granillo GA, Vos J, Bruining N, Investigators of the EUROPA Study, et al. Long-term effect of perindopril on coronary atherosclerosis progression (from the perindopril\u2019s prospective effect on coronary atherosclerosis by angiography and intravascular ultrasound evaluation [PERSPECTIVE] study). Am J Cardiol. 2007;100(2):159\u201363.","journal-title":"Am J Cardiol"},{"key":"150_CR47","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1001\/archinte.166.6.659","volume":"166","author":"R Ferrari","year":"2006","unstructured":"Ferrari R. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med. 2006;166:659\u201366.","journal-title":"Arch Intern Med"},{"key":"150_CR48","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/S0140-6736(05)67186-3","volume":"366","author":"NR Poulter","year":"2005","unstructured":"Poulter NR, Wedel H, Dahl\u00f6f B, ASCOT Investigators, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial- Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet. 2005;366:907\u201313.","journal-title":"Lancet"},{"issue":"10153","key":"150_CR49","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S0140-6736(18)31776-8","volume":"392","author":"A Gupta","year":"2018","unstructured":"Gupta A, Mackay J, Whitehouse A, et al. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. Lancet. 2018;392(10153):1127\u201337.","journal-title":"Lancet"},{"key":"150_CR50","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","volume":"370","author":"Patel A; ADVANCE Collaborative Group","year":"2007","unstructured":"Patel A; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829\u201340.","journal-title":"Lancet"},{"key":"150_CR51","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","volume":"362","author":"KM Fox","year":"2003","unstructured":"Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782\u20138.","journal-title":"Lancet"},{"key":"150_CR52","first-page":"713","volume":"58","author":"AJ Scheen","year":"2003","unstructured":"Scheen AJ. Etude Clinique du mois. L\u2019\u00e9tude EUROPA: protection cardio-vasculaire avec le p\u00e9rindopril chez les patients avec coronaropathie stable. Rev Med Li\u00e8ge. 2003;58:713\u20136.","journal-title":"Rev Med Li\u00e8ge"},{"key":"150_CR53","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","volume":"358","author":"PROGRESS Collaborative Group","year":"2001","unstructured":"PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033\u201341.","journal-title":"Lancet"},{"key":"150_CR54","first-page":"792","volume":"56","author":"AJ Scheen","year":"2001","unstructured":"Scheen AJ. Etude Clinique du mois. Protection secondaire de l\u2019accident vasculaire c\u00e9r\u00e9bral par le p\u00e9rindopril: l\u2019\u00e9tude PROGRESS. Rev Med Li\u00e8ge. 2001;56:792\u20135.","journal-title":"Rev Med Li\u00e8ge"},{"key":"150_CR55","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","volume":"27","author":"JG Cleland","year":"2006","unstructured":"Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J, PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338\u201345.","journal-title":"Eur Heart J"},{"issue":"10","key":"150_CR56","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","volume":"36","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Authors\/Task Force Members, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953\u20132041.","journal-title":"J Hypertens"},{"issue":"3","key":"150_CR57","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.amjmed.2008.09.038","volume":"122","author":"DS Wald","year":"2009","unstructured":"Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122(3):290\u2013300.","journal-title":"Am J Med"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-019-00150-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-019-00150-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-019-00150-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T15:41:24Z","timestamp":1715960484000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-019-00150-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,1]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["150"],"URL":"https:\/\/doi.org\/10.1007\/s40119-019-00150-w","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,1]]},"assertion":[{"value":"27 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}